146 related articles for article (PubMed ID: 9469220)
1. Guidelines for handling antineoplastic and immunosuppressive drugs.
Watson AD; Peaston AE; Malik R; Swinney GR
Aust Vet J; 1997 Dec; 75(12):868-76. PubMed ID: 9469220
[No Abstract] [Full Text] [Related]
2. Weekly methotrexate: harmful to exposed embryos.
Prescrire Int; 2015 Apr; 24(159):98. PubMed ID: 25941703
[No Abstract] [Full Text] [Related]
3. Principles of chemotherapy safety procedures.
Takada S
Clin Tech Small Anim Pract; 2003 May; 18(2):73-4. PubMed ID: 12831064
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic and immunosuppressive drugs. 3. Adverse effects and therapeutic problems.
Cridland MD
Drugs; 1972; 3(5):352-65. PubMed ID: 4569065
[No Abstract] [Full Text] [Related]
5. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress.
Lokich J
Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201
[No Abstract] [Full Text] [Related]
6. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee.
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1005-7. PubMed ID: 4065173
[No Abstract] [Full Text] [Related]
7. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
Mellstedt H; Gimsing P; Waage A
Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
[No Abstract] [Full Text] [Related]
8. The administration of paclitaxel without prophylaxis for the prevention of hypersensitivity reactions: is this a rationale and safe therapeutic strategy?
Markman M
J Cancer Res Clin Oncol; 1997; 123(10):531-2. PubMed ID: 9393585
[No Abstract] [Full Text] [Related]
9. [ESMO 2004. Nausea and vomiting caused by chemotherapy: improving the treatment].
Longo F; Mansueto G
Tumori; 2005; 91(1):suppl 36-48. PubMed ID: 15850022
[No Abstract] [Full Text] [Related]
10. [Methods for optimizing cytostatic drug therapy].
Lipp HP
Med Monatsschr Pharm; 1995 Oct; 18(10):282-91. PubMed ID: 7476654
[No Abstract] [Full Text] [Related]
11. Safe handling and administration of MABS: the guidance.
McGowan D
Br J Nurs; 2015 Sep; 24(16 Suppl 1):S14-20. PubMed ID: 26946647
[TBL] [Abstract][Full Text] [Related]
12. [Reduction and withdrawal of chemotherapy].
Yamaguchi S; Kato S
Nihon Rinsho; 2015 Feb; 73 Suppl 2():79-84. PubMed ID: 25831728
[No Abstract] [Full Text] [Related]
13. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
14. Minimalism in oncology.
The Lancet Oncology
Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
[No Abstract] [Full Text] [Related]
15. [Tapering and termination of immunosuppressive therapy].
Villiger PM; Müller-Ladner U
Z Rheumatol; 2017 Feb; 76(1):6-7. PubMed ID: 28097392
[No Abstract] [Full Text] [Related]
16. A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
Harvey RD; Ratain MJ
JAMA Oncol; 2019 Dec; 5(12):1691-1692. PubMed ID: 31621807
[No Abstract] [Full Text] [Related]
17. [Comments on the contribution, "Immunomodulating staged therapy of multiple sclerosis by the Multiple Sclerosis Therapy Consensus Group"].
Störh M
Nervenarzt; 2002 Dec; 73(12):1207; author reply 1207. PubMed ID: 12599336
[No Abstract] [Full Text] [Related]
18. [Use of targeted drugs in antineoplastic and immunosuppressive therapy].
Ríhová B; Trohalm J; Jelínková M; Stastný M; Hovorka O; Plocová D; Subr V; Ulbrich K
Bratisl Lek Listy; 1998; 99(8-9):439-46. PubMed ID: 9810768
[No Abstract] [Full Text] [Related]
19. [Nursing care of patients with basic multiple sclerosis therapy: preventing relapses].
Balzer K
Pflege Z; 2007 Dec; 60(12):662-3. PubMed ID: 18200980
[No Abstract] [Full Text] [Related]
20. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
Hanauske AR
Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
